Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MVM001
MIFTS: 60

Movement Disease

Categories: Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Movement Disease

About this section

MalaCards integrated aliases for Movement Disease:

Name: Movement Disease 12 15
Movement Disorders 55 43 44 73
Abnormality of Movement 29 6

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:480
MeSH 44 D009069
NCIt 50 C116757
SNOMED-CT 68 60342002
UMLS 73 C0026650
Sources

Summaries for Movement Disease

About this section
MedlinePlus : 43 Imagine if parts of your body moved when you didn't want them to. If you have a movement disorder, you experience these kinds of impaired movement. Dyskinesia is abnormal uncontrolled movement and is a common symptom of many movement disorders. Tremors are a type of dyskinesia. Nerve diseases cause many movement disorders, such as Parkinson's disease. Other causes include injuries, autoimmune diseases, infections and certain medicines. Many movement disorders are inherited, which means they run in families. Treatment varies by disorder. Medicine can cure some disorders. Others get better when an underlying disease is treated. Often, however, there is no cure. In that case, the goal of treatment is to improve symptoms and relieve pain.

MalaCards based summary : Movement Disease, also known as movement disorders, is related to supranuclear palsy, progressive, 1 and stereotypic movement disorder, and has symptoms including ataxia, athetosis and back pain. An important gene associated with Movement Disease is GBA (Glucosylceramidase Beta), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Chks in Checkpoint Regulation. The drugs Fluspirilene and Menthol have been mentioned in the context of this disorder. Affiliated tissues include brain, subthalamic nucleus and testes, and related phenotypes are behavior/neurological and cellular

Sources

Related Diseases for Movement Disease

About this section

Diseases related to Movement Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Related Disease Score Top Affiliating Genes
1 supranuclear palsy, progressive, 1 29.5 DRD2 LRRK2 MAPT PARK7 PRKN SLC6A3
2 stereotypic movement disorder 12.4
3 periodic limb movement disorder 12.3
4 prrt2-associated paroxysmal movement disorders 11.9
5 extrapyramidal and movement disease 11.9
6 multifocal dystonia 10.9 ATP1A3 TOR1A
7 hereditary late-onset parkinson disease 10.9 GBA LRRK2 SNCA
8 oromandibular dystonia 10.8 GCH1 TOR1A
9 rem sleep behavior disorder 10.8 LRRK2 SLC6A3 SNCA
10 segmental dystonia 10.7 GCH1 TOR1A
11 focal dystonia 10.7 DRD2 SGCE TOR1A
12 striatonigral degeneration 10.7 DRD2 SLC6A3 SNCA
13 postencephalitic parkinson disease 10.7 LRRK2 MAPT SNCA
14 corticobasal degeneration 10.7 GBA LRRK2 MAPT
15 hereditary dystonia 10.6 GCH1 TH
16 cocaine abuse 10.6 DRD2 SLC6A3 SNCA
17 akinetic mutism 10.6 MAPT SLC6A3
18 aphasia 10.6 LRRK2 MAPT SNCA
19 hyperphenylalaninemia, bh4-deficient, b 10.6 GCH1 TH
20 segawa syndrome, autosomal recessive 10.5 GCH1 TH
21 perry syndrome 10.5 SLC6A3 SNCA TH
22 pathological gambling 10.5 DRD2 DRD3 SLC6A3
23 neurodegeneration with brain iron accumulation 10.5 FTL PANK2 SNCA
24 alcohol-induced mental disorder 10.5 DRD2 SLC6A3
25 leukodystrophy, hypomyelinating, 2 10.5 GCH1 HTT PANK2 TOR1A
26 gilles de la tourette syndrome 10.5 DRD2 SGCE SLC6A3
27 toxic encephalopathy 10.5 SLC6A3 SNCA TH
28 hemidystonia 10.5 ATP1A3 GCH1 SGCE SNCA TOR1A
29 cocaine dependence 10.5 DRD2 DRD3 SLC6A3
30 dystonia 1, torsion, autosomal dominant 10.5 GCH1 SGCE TH TOR1A
31 mirror movements 1 10.4
32 stiff-person syndrome 10.4
33 choreatic disease 10.4
34 personality disorder 10.4 DRD2 DRD3 SLC6A3
35 substance abuse 10.4 DRD2 DRD3 SLC6A3
36 dystonia 12 10.4 ATP1A3 GCH1 PANK2 SGCE TOR1A
37 substance dependence 10.4 DRD2 DRD3 SLC6A3
38 delusional disorder 10.4 DRD2 DRD3 TH
39 aceruloplasminemia 10.4 ATP1A3 FTL PANK2 SNCA
40 early-onset schizophrenia 10.3 DRD2 DRD3 TH
41 opiate dependence 10.3 DRD2 DRD3 TH
42 obsessive-compulsive disorder 10.3 DRD2 DRD3 SGCE SLC6A3
43 parkinson disease 10 10.3 LRRK2 PARK7 PINK1 PRKN SNCA
44 parkinson disease 2, autosomal recessive juvenile 10.3 LRRK2 PARK7 PINK1 PRKN SNCA
45 polysubstance abuse 10.3 DRD2 DRD3
46 migraine with or without aura 1 10.3 ATP1A3 DRD2 DRD3 SLC6A3
47 alcohol dependence 10.2 DRD2 DRD3 SLC6A3 SNCA
48 parkinson disease 3, autosomal dominant 10.2 LRRK2 MAPT PARK7 PRKN SNCA
49 early-onset parkinson's disease 10.1 GBA LRRK2 PARK7 PINK1 PRKN SNCA
50 dystonia, dopa-responsive 10.0 ATP1A3 GCH1 SGCE SLC6A3 TH TOR1A

Graphical network of the top 20 diseases related to Movement Disease:



Diseases related to Movement Disease
Sources

Symptoms & Phenotypes for Movement Disease

About this section

UMLS symptoms related to Movement Disease:


ataxia, athetosis, back pain, dystonia, headache, leg cramps, muscle cramp, myoclonus, pain, sciatica, seizures, spasm, syncope, torticollis, tremor, chronic pain, cogwheel rigidity, spasmodic torticollis, muscle fibrillation, asterixis, clumsiness, hyperexplexia, akathisia, involuntary movements, vertigo/dizziness, myokymia, sleeplessness, symptoms, pseudobulbar signs

MGI Mouse Phenotypes related to Movement Disease:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.5 DRD3 ATP1A3 FMR1 GAMT DRD2 GBA
2 cellular MP:0005384 10.43 FMR1 GAMT DRD2 GBA PARK7 MAPT
3 homeostasis/metabolism MP:0005376 10.41 GBA DRD3 GCH1 ATP1A3 GAMT DRD2
4 growth/size/body region MP:0005378 10.4 GBA DRD3 ATP1A3 FMR1 GAMT DRD2
5 cardiovascular system MP:0005385 10.31 GBA DRD3 DRD2 LRRK2 GCH1 MAPT
6 mortality/aging MP:0010768 10.31 GBA DRD3 GCH1 ATP1A3 GAMT DRD2
7 nervous system MP:0003631 10.28 DRD3 GCH1 ATP1A3 FMR1 DRD2 GBA
8 endocrine/exocrine gland MP:0005379 10.25 GBA FMR1 GAMT DRD2 PANK2 LRRK2
9 immune system MP:0005387 10.2 DRD2 GBA ATP1A3 PANK2 LRRK2 MAPT
10 integument MP:0010771 10.13 DRD2 GBA FMR1 LRRK2 MAPT HTT
11 muscle MP:0005369 9.97 DRD2 ATP1A3 PANK2 MAPT PRKN SGCE
12 no phenotypic analysis MP:0003012 9.86 DRD2 LRRK2 MAPT HTT PRKN SNCA
13 normal MP:0002873 9.85 DRD2 GBA LRRK2 MAPT HTT PRKN
14 renal/urinary system MP:0005367 9.5 DRD2 DRD3 GAMT PANK2 LRRK2 MAPT
15 taste/olfaction MP:0005394 9.1 DRD2 MAPT HTT SLC6A3 PINK1 SNCA
Sources

Drugs & Therapeutics for Movement Disease

About this section

Drugs for Movement Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 622)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluspirilene Approved, Investigational Phase 4 1841-19-6 3396
2
Menthol Approved Phase 4,Phase 2,Not Applicable,Early Phase 1 2216-51-5 16666
3
Nicotine Approved Phase 4,Phase 2,Phase 1,Not Applicable 54-11-5 942 89594
4
Memantine Approved, Investigational Phase 4,Phase 2,Not Applicable 19982-08-2 4054
5
Rivastigmine Approved, Investigational Phase 4,Phase 3,Phase 2 123441-03-2 77991
6
Midodrine Approved Phase 4,Phase 1,Not Applicable 133163-28-7, 42794-76-3 4195
7
Clonidine Approved Phase 4,Phase 3,Phase 2,Not Applicable 4205-90-7 2803
8
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
9
Fluphenazine Approved Phase 4 69-23-8 3372
10
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
11
Clozapine Approved Phase 4,Phase 3,Not Applicable 5786-21-0 2818
12
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
13
Galantamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 357-70-0 9651
14
Modafinil Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 68693-11-8 4236
15
Carbidopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28860-95-9 34359 38101
16
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
17
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
18
Zonisamide Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 68291-97-4 5734
19
Pimozide Approved Phase 4,Phase 2 2062-78-4 16362
20 Piracetam Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 7491-74-9
21
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 91374-20-8, 91374-21-9 5095 497540
22
Pramipexole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104632-26-0 59868 119570
23
Iodine Approved, Investigational Phase 4,Phase 2 7553-56-2 807
24
Entacapone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130929-57-6 5281081
25
Rasagiline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 136236-51-6 3052776
26
Sulpiride Approved, Investigational Phase 4 15676-16-1 5355
27
Aripiprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 129722-12-9 60795
28 bromperidol Approved, Investigational Phase 4 10457-90-6 2448
29
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
30 Benperidol Approved, Investigational Phase 4 2062-84-2
31
Levodopa Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-92-7 6047
32
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
33
Perphenazine Approved Phase 4,Phase 2 58-39-9 4748
34
Amantadine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 768-94-5 2130
35
Haloperidol Approved Phase 4,Phase 2,Not Applicable 52-86-8 3559
36
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
37
Tetrabenazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-46-8 6018
38
Apomorphine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 41372-20-7, 58-00-4 6005
39
Donepezil Approved Phase 4,Phase 3,Phase 2,Not Applicable 120014-06-4 3152
40 Opicapone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 923287-50-7
41
Armodafinil Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 112111-43-0
42 Perazine Approved, Investigational Phase 4 84-97-9
43
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2 7440-66-6 23994
44
Lubiprostone Approved, Investigational Phase 4,Not Applicable 136790-76-6 656719
45
Benserazide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 322-35-0
46
Riluzole Approved, Investigational Phase 4,Phase 3,Phase 2 1744-22-5 5070
47
Cabergoline Approved Phase 4,Phase 3,Not Applicable 81409-90-7 54746
48
Topiramate Approved Phase 4,Phase 3,Phase 2,Not Applicable 97240-79-4 5284627
49
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
50
Guanfacine Approved, Investigational Phase 4,Phase 3 29110-47-2 3519

Interventional clinical trials:

(show top 50) (show all 3021)
# Name Status NCT ID Phase Drugs
1 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
2 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
3 The Use of Botox in Advanced Parkinson's Patients Experiencing Pain Unknown status NCT02472210 Phase 4 Botulinum Toxin
4 Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism Unknown status NCT01336439 Phase 4 Botulinum toxin type A (Meditoxin®)
5 The Effect of Donepezil on Gait and Balance in Parkinson's Disease Unknown status NCT01521117 Phase 4 Donepezil
6 Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients Unknown status NCT02307396 Phase 4 Olanzapine;Amisulpride;Risperidone;Haloperidol;Quetiapine;Perphenazine;Sulpiride;bromperidol;Zuclopenthixol;Thioridazine;Paliperidone;Ziprasidone;Benperidol;Fluspirilene;Pimozide;Perazine;Fluphenazine;Flupentixole;Sertindole
7 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4 Nuronox
8 Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia Unknown status NCT00142259 Phase 4
9 Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia Unknown status NCT00837707 Phase 4 aripiprazole
10 Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease Unknown status NCT02768077 Phase 4 Melatonin(Circadin®);Placebo
11 Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area Unknown status NCT01782638 Phase 4
12 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients Unknown status NCT01780467 Phase 4
13 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study Unknown status NCT01765257 Phase 4 AZILECT®;Placebo
14 Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID) Unknown status NCT01515774 Phase 4 Mirapex ER
15 Emotion, Mood and Executive Function in Parkinson`s Disease (PD) Unknown status NCT01385735 Phase 4 Rasagiline;Placebo
16 Cognitive Decline in Non-demented PD Unknown status NCT01340885 Phase 4 Strattera;Exelon
17 The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy Unknown status NCT01313819 Phase 4 PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj
18 Nicotine Treatment of Impulsivity in Parkinson's Disease Unknown status NCT01216904 Phase 4 nicotine patch;placebo
19 A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients Unknown status NCT01007630 Phase 4 Rasagiline;Placebo
20 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4 Intravesical injection of Botulinum A toxin
21 Use of Interventional MRI for Implantation of Deep Brain Stimulator Electrodes Unknown status NCT00792532 Phase 4
22 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease Unknown status NCT00696215 Phase 4 placebo;rasagiline
23 Study of Memantine to Treat Huntington's Disease Unknown status NCT00652457 Phase 4 Memantine
24 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
25 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4 APO-clonidine
26 Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
27 A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms Completed NCT00382967 Phase 4
28 Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists Completed NCT00443872 Phase 4 orally disintegrating selegiline (Zelapar)
29 Treatment of Tardive Dyskinesia With Galantamine Completed NCT00164242 Phase 4 Galantamine
30 Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia Completed NCT00114595 Phase 4 eicosapentaenoic acid
31 Propranolol and Botulinum Toxin for Essential Vocal Tremor Completed NCT02111369 Phase 4 Propranolol
32 Tardive Dyskinesia and Cognitive Function Completed NCT00926965 Phase 4 amisulpride;Olanzapine;Conventional antipsychotics
33 Investigation of the Use of Remote Presence Robots in Delivery of Neuromodulation Completed NCT01283633 Phase 4
34 Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) Completed NCT01770145 Phase 4 APOKYN;L-dopa;Trimethobenzamide
35 Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease Completed NCT00526630 Phase 4 Methylphenidate (MPD);Placebo
36 Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia Completed NCT00208091 Phase 4 Botulinum toxin, type B
37 Neurotoxin and Physical Therapy Completed NCT02177617 Phase 4 Botox injection
38 Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease Completed NCT01662414 Phase 4
39 Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment Completed NCT00489255 Phase 4 Tigan®;Placebo
40 Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease Completed NCT00640159 Phase 4 Zelapar
41 Stalevo in Early Wearing-Off Patients Completed NCT00125567 Phase 4 Stalevo (levodopa/carbidopa/entacapone);Levodopa/carbidopa
42 Validation of Dyskinesia Rating Scales Completed NCT01071395 Phase 4 Amantadine;Placebo
43 Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed NCT00043849 Phase 4 Quetiapine
44 A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis Completed NCT00644800 Phase 4 Ziprasidone
45 A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients Completed NCT00634348 Phase 4 Aripiprazole;Ziprasidone
46 Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia Completed NCT01726335 Phase 4 Risperidone prolonged release
47 A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs Completed NCT00649064 Phase 4 Ziprasidone
48 Brexpiprazole for Bipolar Depression Completed NCT03427892 Phase 4 Brexpiprazole
49 Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia Completed NCT00492336 Phase 4 rasagiline (Pharmacodynamics);Placebo
50 An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment Completed NCT00526877 Phase 4 Risperidone

Search NIH Clinical Center for Movement Disease

Cochrane evidence based reviews: movement disorders

Sources

Genetic Tests for Movement Disease

About this section

Genetic tests related to Movement Disease:

# Genetic test Affiliating Genes
1 Abnormality of Movement 29
Sources

Anatomical Context for Movement Disease

About this section

MalaCards organs/tissues related to Movement Disease:

41
Brain, Subthalamic Nucleus, Testes, Cortex, Eye, Bone, Heart
Sources

Publications for Movement Disease

About this section

Articles related to Movement Disease:

(show top 50) (show all 415)
# Title Authors Year
1
More than ataxia - Movement disorders in ataxia-telangiectasia. ( 29249681 )
2018
2
Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. ( 29423615 )
2018
3
Hemizygous UBA5 missense mutation unmasks recessive disorder in a patient with infantile-onset encephalopathy, acquired microcephaly, small cerebellum, movement disorder and severe neurodevelopmental delay. ( 29902590 )
2018
4
Movement disorders in non-encephalopathic Hashimoto's thyroiditis. ( 29887356 )
2018
5
Reflections on 50 Years of Neuroscience Nursing: Movement Disorders, Neuromuscular Disease, and Multiple Sclerosis. ( 29266080 )
2018
6
Ataxia-telangiectasia: A review of movement disorders, clinical features, and genotype correlations. ( 29436738 )
2018
7
An assessment of Movement Disorder Society Task Force diagnostic criteria for mild cognitive impairment in Parkinson's disease. ( 28941002 )
2018
8
Defining Hand Stereotypies in Rett Syndrome: A Movement Disorders Perspective. ( 28838622 )
2017
9
GNAO1-associated epileptic encephalopathy and movement disorders: c.607G>A variant represents a probable mutation hotspot with a distinct phenotype. ( 28202424 )
2017
10
Dystonia as an unusual presentation of systemic mastocytosis: possible link between histamine release and movement disorders. ( 28757371 )
2017
11
Secondary Repair of Posttraumatic Enophthalmos and Extraocular Movement Disorders. ( 29195241 )
2017
12
Pharmacological Management of Restless Legs Syndrome and Periodic Limb Movement Disorder in Children. ( 28831753 )
2017
13
ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. ( 28511835 )
2017
14
Should oral iron be first-line therapy for pediatric restless legs syndrome and periodic limb movement disorder? ( 28279575 )
2017
15
Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative ataxia group, and tremor research group. ( 28887904 )
2017
16
Personality traits in psychogenic nonepileptic seizures (PNES) and psychogenic movement disorder (PMD): Neuroticism and perfectionism. ( 28606495 )
2017
17
The most promising advances in our understanding and treatment of functional (psychogenic) movement disorders. ( 28709746 )
2017
18
Multiple system atrophy: insights into a rare and debilitating movement disorder. ( 28303913 )
2017
19
Psychogenic Movement Disorders and Dopamine Transporter Scans: Still a Clinical Diagnosis? ( 27889083 )
2017
20
Synaptic UNC13A protein variant causes increased neurotransmission and dyskinetic movement disorder. ( 28192369 )
2017
21
Hypersomnolence-hyperkinetic movement disorder in a child with compound heterozygous mutation in 4-aminobutyrate aminotransferase (ABAT) gene. ( 27596361 )
2017
22
Neuroprotective Effects of Exercise on Brain Edema and Neurological Movement Disorders Following the Cerebral Ischemia and Reperfusion in Rats. ( 28446953 )
2017
23
BCAP31-associated encephalopathy and complex movement disorder mimicking mitochondrial encephalopathy. ( 28332767 )
2017
24
Periodic Limb Movements During Sleep Mimicking REM Sleep Behavior Disorder: A New Form of Periodic Limb Movement Disorder. ( 28364416 )
2017
25
Hyperkinetic psychogenic movement disorders remain a diagnosis at first sight. ( 27913698 )
2017
26
Novel Eye Movement Disorders in Whipple's Disease-Staircase Horizontal Saccades, Gaze-Evoked Nystagmus, and Esotropia. ( 28744253 )
2017
27
Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. ( 28509336 )
2017
28
While Isolated Periodic Limb Movement Disorder Significantly Impacts Sleep Depth and Efficiency, Co-Morbid Restless Leg Syndrome Mainly Exacerbates Perceived Sleep Quality. ( 28391285 )
2017
29
Movement disorder in GNAO1 encephalopathy associated with gain-of-function mutations. ( 28747448 )
2017
30
Psychodynamic Psychotherapy for Functional (Psychogenic) Movement Disorders. ( 28122424 )
2017
31
Movement Disorders in 18p Deletion Syndrome: A Case Report and Review of Literature. ( 28137337 )
2017
32
Gender and Age Determinants of Psychogenic Movement Disorders: A Clinical Profile of 73 Patients. ( 26757796 )
2016
33
Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders. ( 27414076 )
2016
34
A movement disorder with dystonia and ataxia caused by a mutation in the HIBCH gene. ( 27400804 )
2016
35
The expanding phenotypic spectrum of ARFGEF2 gene mutation: Cardiomyopathy and movement disorder. ( 26126837 )
2016
36
Recurrent GNAO1 mutations associated with developmental delay and a movement disorder. ( 27625011 )
2016
37
Clinical course of six children with GNAO1 mutations causing a severe and distinctive movement disorder. ( 27068059 )
2016
38
Stiff person syndrome and other immune-mediated movement disorders - new insights. ( 27262149 )
2016
39
Facial movement disorder and dopamine imaging in a patient with amphetamine abuse. ( 27502592 )
2016
40
Spectrum of Movement Disorders in Mitochondrial Disorders-Reply. ( 27479912 )
2016
41
Spectrum of Movement Disorders in Mitochondrial Disorders. ( 27479845 )
2016
42
Spontaneous Intracranial Hypotension and its Association with Movement Disorders? ( 27897276 )
2016
43
Obstructive sleep apnea and periodic limb movement disorder in a population of children with hypertension and/or nocturnal nondipping blood pressures. ( 26725017 )
2016
44
Bruxism in Movement Disorders: A Comprehensive Review. ( 27077925 )
2016
45
Cognitive Behavioural Therapy and Adjunctive Physical Activity for Functional Movement Disorders (Conversion Disorder): A Pilot, Single-Blinded, Randomized Study. ( 27744440 )
2016
46
Movement Disorders Associated With Hemochromatosis. ( 27827297 )
2016
47
Clinical, Genetic, and Radiological Features of Extrapyramidal Movement Disorders in Mitochondrial Disease. ( 27111573 )
2016
48
Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis. ( 27100392 )
2016
49
Examiner manoeuvres 'sensory tricks' in functional (psychogenic) movement disorders. ( 27986829 )
2016
50
Psychogenic movement disorder in human T-lymphotropic virus type 1 associated myelopathy. ( 26603645 )
2016
Sources

Variations for Movement Disease

About this section

ClinVar genetic disease variations for Movement Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 GBA NM_000157.3(GBA): c.1448T> C (p.Leu483Pro) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs421016 GRCh37 Chromosome 1, 155205043: 155205043
2 GBA NM_000157.3(GBA): c.1448T> C (p.Leu483Pro) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs421016 GRCh38 Chromosome 1, 155235252: 155235252
3 46;XY;t(1;6)(q23;q13)dn Translocation Uncertain significance
4 ITPR1 NM_001168272.1(ITPR1): c.2432C> T (p.Ser811Phe) single nucleotide variant Uncertain significance GRCh37 Chromosome 3, 4715906: 4715906
5 ITPR1 NM_001168272.1(ITPR1): c.2432C> T (p.Ser811Phe) single nucleotide variant Uncertain significance GRCh38 Chromosome 3, 4674222: 4674222

Copy number variations for Movement Disease from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 262562 X 37500000 47300000 Deletion MAOA Movement disorder
2 262566 X 37500000 47300000 Deletion MAOB Movement disorder
Sources

Expression for Movement Disease

About this section
Search GEO for disease gene expression data for Movement Disease.
Sources

Pathways for Movement Disease

About this section

Pathways related to Movement Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 66
Show member pathways
 13.21 DRD2 HTT LRRK2 MAPT PARK7 PINK1
2
Chks in Checkpoint Regulation 64
Show member pathways
 12.33 PARK7 PINK1 PRKN SLC6A3 SNCA
3
Neuroscience 4
11.86 FMR1 HTT LRRK2 MAPT PARK7 PINK1
4
Parkinsons Disease Pathway 1
11.62 LRRK2 PARK7 PINK1 PRKN SLC6A3 SNCA
5
Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics 61
Show member pathways
 11.55 DRD2 DRD3 TH
6
Alpha-synuclein signaling 1
10.94 PARK7 PRKN SLC6A3 SNCA TH TOR1A
Sources

GO Terms for Movement Disease

About this section

Cellular components related to Movement Disease according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.87 DRD2 FMR1 HTT LRRK2 MAPT SGCE
2 cytoplasmic vesicle membrane GO:0030659 9.84 HTT SNCA TH TOR1A
3 synaptic vesicle GO:0008021 9.81 LRRK2 SNCA TH TOR1A
4 perikaryon GO:0043204 9.8 DRD2 FMR1 LRRK2 TH
5 neuronal cell body GO:0043025 9.8 ATP1A3 FMR1 LRRK2 MAPT SLC6A3 SNCA
6 cell body GO:0044297 9.77 MAPT PARK7 PINK1
7 terminal bouton GO:0043195 9.76 LRRK2 SNCA TH
8 postsynapse GO:0098794 9.74 FMR1 LRRK2 SNCA
9 axon terminus GO:0043679 9.73 DRD2 FMR1 SNCA
10 presynapse GO:0098793 9.71 FMR1 PARK7 PRKN SLC6A3
11 mitochondrial intermembrane space GO:0005758 9.67 PANK2 PARK7 PINK1 SNCA
12 growth cone GO:0030426 9.63 FMR1 LRRK2 MAPT PINK1 SNCA TOR1A
13 inclusion body GO:0016234 9.61 HTT LRRK2 SNCA
14 autolysosome GO:0044754 9.59 FTL LRRK2
15 neuron projection GO:0043005 9.56 FMR1 LRRK2 MAPT PARK7 PRKN SLC6A3
16 Lewy body GO:0097413 9.52 PINK1 PRKN
17 axon GO:0030424 9.36 ATP1A3 DRD2 FMR1 HTT LRRK2 MAPT
18 cytoplasm GO:0005737 10.36 FMR1 FTL GAMT GCH1 HTT LRRK2
19 cytosol GO:0005829 10.32 FMR1 FTL GAMT GCH1 HTT LRRK2
20 mitochondrion GO:0005739 10.18 LRRK2 MAPT PANK2 PARK7 PINK1 PRKN
21 cell projection GO:0042995 10.09 DRD3 FMR1 LRRK2 MAPT SGCE TOR1A
22 perinuclear region of cytoplasm GO:0048471 10.02 FMR1 HTT PARK7 PINK1 PRKN SNCA
23 synapse GO:0045202 10 ATP1A3 FMR1 LRRK2 SNCA TOR1A

Biological processes related to Movement Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron apoptotic process GO:0043524 9.98 PARK7 PINK1 PRKN SNCA
2 response to oxidative stress GO:0006979 9.97 LRRK2 PINK1 PRKN TOR1A
3 response to ethanol GO:0045471 9.95 DRD2 DRD3 SLC6A3 TH
4 autophagy GO:0006914 9.93 DRD2 DRD3 LRRK2 PARK7 PINK1 PRKN
5 mitochondrion organization GO:0007005 9.92 GBA LRRK2 PARK7 PINK1 PRKN
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.91 PARK7 PINK1 SNCA
7 cellular response to oxidative stress GO:0034599 9.91 LRRK2 PARK7 PINK1 SNCA
8 locomotory behavior GO:0007626 9.91 DRD2 DRD3 PRKN SLC6A3 TH
9 excitatory postsynaptic potential GO:0060079 9.9 DRD2 LRRK2 SNCA
10 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.9 GBA LRRK2 PRKN
11 negative regulation of cell death GO:0060548 9.9 DRD2 PARK7 PRKN
12 regulation of autophagy GO:0010506 9.89 LRRK2 MAPT PRKN
13 learning GO:0007612 9.89 DRD3 PRKN TH
14 adult locomotory behavior GO:0008344 9.88 PARK7 PRKN SNCA
15 protein destabilization GO:0031648 9.87 HTT PRKN SNCA
16 response to nicotine GO:0035094 9.86 DRD2 SLC6A3 TH
17 response to cocaine GO:0042220 9.86 DRD2 DRD3 SLC6A3 SNCA
18 negative regulation of protein phosphorylation GO:0001933 9.83 DRD2 LRRK2 PARK7 PRKN SNCA
19 negative regulation of blood pressure GO:0045776 9.82 DRD2 DRD3 GCH1
20 response to amphetamine GO:0001975 9.81 DRD2 DRD3 TH
21 regulation of reactive oxygen species metabolic process GO:2000377 9.79 PINK1 PRKN SNCA
22 behavioral response to cocaine GO:0048148 9.78 DRD2 DRD3 SNCA
23 regulation of mitochondrial membrane potential GO:0051881 9.78 PANK2 PARK7 PINK1 PRKN
24 regulation of neurotransmitter secretion GO:0046928 9.77 FMR1 PRKN SNCA
25 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.77 LRRK2 PARK7 PRKN
26 negative regulation of protein secretion GO:0050709 9.76 DRD2 DRD3
27 regulation of protein ubiquitination GO:0031396 9.76 PINK1 PRKN
28 synaptic vesicle transport GO:0048489 9.76 SNCA TOR1A
29 prepulse inhibition GO:0060134 9.76 DRD2 DRD3 SLC6A3
30 regulation of mitochondrion organization GO:0010821 9.75 PINK1 PRKN
31 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.75 LRRK2 PARK7
32 startle response GO:0001964 9.75 DRD2 PRKN
33 positive regulation of mitochondrial fission GO:0090141 9.75 PINK1 PRKN
34 microglial cell activation GO:0001774 9.75 MAPT SNCA
35 positive regulation of renal sodium excretion GO:0035815 9.75 DRD2 DRD3
36 neurotransmitter biosynthetic process GO:0042136 9.75 SLC6A3 TH
37 regulation of locomotion GO:0040012 9.75 DRD3 LRRK2 SNCA
38 negative regulation of voltage-gated calcium channel activity GO:1901386 9.74 DRD2 FMR1
39 negative regulation of macroautophagy GO:0016242 9.74 LRRK2 PINK1
40 cellular response to dopamine GO:1903351 9.74 LRRK2 PRKN
41 negative regulation of autophagosome assembly GO:1902902 9.74 LRRK2 PINK1
42 supramolecular fiber organization GO:0097435 9.74 MAPT SNCA
43 negative regulation of oxidative stress-induced neuron death GO:1903204 9.74 PARK7 PINK1
44 striatum development GO:0021756 9.74 DRD2 LRRK2
45 positive regulation of autophagy of mitochondrion GO:1903599 9.74 HTT PARK7 PRKN
46 G-protein coupled receptor internalization GO:0002031 9.73 DRD2 DRD3
47 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.73 DRD2 DRD3
48 regulation of dopamine metabolic process GO:0042053 9.73 PRKN SLC6A3
49 adenohypophysis development GO:0021984 9.72 DRD2 SLC6A3
50 intracellular distribution of mitochondria GO:0048312 9.72 LRRK2 MAPT

Molecular functions related to Movement Disease according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.97 DRD2 FMR1 GCH1 LRRK2 MAPT PARK7
2 microtubule binding GO:0008017 9.81 FMR1 LRRK2 MAPT SNCA
3 chaperone binding GO:0051087 9.72 ATP1A3 MAPT PRKN
4 kinase binding GO:0019900 9.7 HTT PARK7 PRKN
5 enzyme binding GO:0019899 9.65 MAPT PARK7 PRKN SNCA TH
6 drug binding GO:0008144 9.61 DRD2 DRD3 SLC6A3
7 identical protein binding GO:0042802 9.61 DRD2 FMR1 FTL HTT LRRK2 MAPT
8 ubiquitin-specific protease binding GO:1990381 9.57 PARK7 PRKN
9 phospholipase binding GO:0043274 9.54 PRKN SNCA
10 tubulin binding GO:0015631 9.5 LRRK2 MAPT PRKN
11 dynactin binding GO:0034452 9.48 HTT MAPT
12 ferric iron binding GO:0008199 9.46 FTL TH
13 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.4 DRD2 DRD3
14 cuprous ion binding GO:1903136 9.37 PARK7 SNCA
15 dopamine neurotransmitter receptor activity GO:0004952 9.16 DRD2 DRD3
16 dopamine binding GO:0035240 8.92 DRD2 DRD3 SLC6A3 TH
17 protein binding GO:0005515 10.49 DRD2 DRD3 FMR1 FTL GBA GCH1
Sources

Sources for Movement Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....